Purdue University researchers have developed a method of using nanoparticles to deliver treatments to injured brain and spinal cord cells. A team led by Richard Borgens of the School of Veterinary Medicine's Center for Paralysis Research and Welden School of Biomedical Engineering coated silica nanoparticles with a polymer to target and repair injured guinea pig spinal cords. That research is being published in the October edition of the journal Small.
The team then used the coated nanoparticles to deliver both the polymer and hydralazine to cells with secondary damage from a naturally produced toxin. That research was published in August by the journal Nanomedicine.
Borgens' group had previously shown benefits of the polymer polyethylene glycol, or PEG, to treat rats with brain injuries and dogs with spinal cord injuries. PEG specifically targets damaged cells and seals the injured area, reducing further damage. It also helps restore cell function, Borgens said.
In previous studies, PEG was mixed with saline and injected.
"Composition and concentration limited how much PEG we could get to the injury," he said.
"If you change the composition to make the PEG more potent, it produces ethylene glycol, the poison in antifreeze. If you change the concentration of PEG in another way, the solution becomes syrupy and difficult to inject."
So the team - which includes Youngnam Cho of the Center for Paralysis Research, Riyi Shi of the center and Weldon School, and Albena Ivanisevic of Weldon School and the Department of Chemistry - turned to silica nanoparticles.
"These particles are so tiny they can't be seen with a regular microscope. They are about the size of a large virus. So you can inject as many as you need. And they are safe inside bodies," Borgens said.
In the first study, the researchers coated the nanoparticles with PEG to treat guinea pig spinal cord injuries. The treated spinal cord cells showed improved physiological functioning.
In the second study, the researchers added both PEG and hydralazine, an antihypertension drug, to mesoporous silica nanoparticles. These nanoparticles have pores that can hold the drug, which is later delivered to the damaged cells. The hydralazine was added to fight off secondary damage to cells that occurs after the initial injury.
"When cells are injured, they produce natural toxins," Borgens said. "Acrolein is the most poisonous of these toxins. It's an industrial hazard for which hydralazine is an antidote."
Borgens and his team introduced acrolein into cells and then treated the cells with different combinations of hydralazine and/or PEG delivered by the mesoporous silica nanoparticles.
They found that the treatment restored disrupted cell function caused by acrolein.
The team concluded that the use of nanoparticles to deliver both PEG and hydralazine increased the effectiveness of earlier PEG-only treatment by controlling and concentrating release of the drug and the polymer, producing a dual treatment and prolonging the treatment's duration.
The goal of Borgens' research is to improve the quality of life of those who have suffered head or spinal cord injuries.
"All ambulances should have PEG on board," he said. "It can probably save thousands of people from more severe head and spinal damage."
Source: Purdue University
Related stories:
Researchers use nanoparticles to deliver treatment for brain, spinal cord injuries
Purdue University researchers have developed a method of using nanoparticles to deliver treatments to injured brain and spinal cord cells. A team led by Richard Borgens of the School of Veterinary Medicine's Center for Paralysis Research and Welden School of Biomedical Engineering coated silica nanoparticles with a polymer to target and repair injured guinea pig spinal cords. That research is being published in the October edition of the journal
Small.
Reversible 3-D cell culture gel invented
Singapore's Institute of Bioengineering and Nanotechnology (IBN), which celebrates its fifth anniversary this year, has invented a unique user-friendly gel that can liquefy on demand, with the potential to revolutionize three-dimensional (3D) cell culture for medical research.
Hybrid Nanoparticles Image and Treat Tumors
(PhysOrg.com) -- By combining a magnetic nanoparticle, a fluorescent quantum dot, and an anticancer drug within a lipid-based nanoparticle, a multi-institutional research team headed by members of the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer has created a single agent that can image and treat tumors. In addition, this new nanoparticle is able to avoid detection by the immune system, enabling the particle to remain in the body for extended periods of time.
Switchable bio-adhesion
(PhysOrg.com) -- Researchers have developed a new type of property-changing polymer: It is water-repellent at 37°C, which makes it an ideal culture substrate for biological cells. At room temperature it attracts water, allowing the cells to be detached easily from the substrate.
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus — regarded by many as nearly impenetrable — and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
(PhysOrg.com) -- The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.
Cancer drug delivery research cuts time from days to hours
Researchers at Case Western Reserve University have developed a technique that has the potential to deliver cancer-fighting drugs to diseased areas within hours, as opposed to the two days it currently takes for existing delivery systems.
Improved culture system for hepatitis C virus infection
A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment to evaluate possible treatments. The novel cell line, described in the July 16 issue of
PLoS ONE, will allow pharmaceutical companies to effectively test new drug candidates or possible vaccines for the HCV infection, which afflicts about 170 million people worldwide. Currently, there is no animal model that is effective for testing such therapies.